Form 4: Eliem Therapeutics Director, Liam Ratcliffe, Acquires 10,000 Stock Options

Director Liam Ratcliffe acquired 10,000 stock options in Eliem Therapeutics, Inc. on June 26, 2024.

Summary

• Liam Ratcliffe, a director of Eliem Therapeutics, Inc. (ELYM), acquired 10,000 stock options on June 26, 2024.
• The exercise price of these options is $7.89.
• The options vest on the earlier of June 26, 2025, or the day before the next annual meeting of stockholders, contingent upon continuous service.
• The options expire on June 25, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director. The acquisition itself can be seen as a slightly positive signal, but the filing is primarily informational.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.

Key Dates